Lipum
17.2
SEK
+1.78 %
LIPUM
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+1.78%
+21.13%
+32.31%
+166.67%
+174.01%
+97.19%
-5.58%
-
-21.35%
lipum.se
Lipum is a biopharmaceutical company. The company is in the clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in the clinical phase with preclinical data for rheumatism. The company is also evaluating other inflammatory diseases. Lipum has its operations in Umeå.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LIPUM
Daily low / high price
17 / 17.6
SEK
Market cap
364.85M SEK
Turnover
67.62K SEK
Volume
4K
Financial calendar
Annual report
2025-02-26
Interim report
2025-04-24
General meeting
2025-05-14
Interim report
2025-08-14
Interim report
2025-10-23
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Flerie Invest AB | 56.8 % | 56.8 % |
| Crafoordska Stiftelsen | 6.1 % | 6.1 % |
| Avanza Pension | 6.0 % | 6.0 % |
| Nordnet Pensionsförsäkring AB | 5.8 % | 5.8 % |
| Christian von Koenigsegg | 3.3 % | 3.3 % |
| Tibia Konsult AB | 2.6 % | 2.6 % |
| Adam Dahlberg | 2.0 % | 2.0 % |
| Ulf Andersson | 1.3 % | 1.3 % |
| Göran Källebo | 1.3 % | 1.3 % |
| Movestic Livförsäkring AB | 1.2 % | 1.2 % |
ShowingAll content types
Lipum AB: BioStock: Lipum presents promising phase I data at ACR 2024
Lipum presenterar lovande data för den nya antikroppen SOL-116 vid ACR 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools